PALACOS E-FLOW (OSTEOPAL) BONE CEMENT

FDA Premarket Approval P810020 S004

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for changes in the bone cement composition. The device, as modified, will be marketed under the trade name osteopal (e-flow) and is indicated for use as a bone cement in arthroplastic procedures of the hip, knee, and other joins to fix plastic and metal prosthetic parts to living bone when recondstruction is necessary because of osteoarthritis, nonunion of fractures of the neck of the femur, sickle cell anemai, osteoporosis, secondary severe joint destruction following trauma or toehr conditions (also for fixation of unstable fractures in metastatic malignancies), and revision of previous arthroplasty procedures.

DevicePALACOS E-FLOW (OSTEOPAL) BONE CEMENT
Generic NameBone Cement
ApplicantSMITH & NEPHEW RICHARDS, INC.
Date Received1995-07-20
Decision Date1998-07-30
PMAP810020
SupplementS004
Product CodeLOD 
Advisory CommitteeOrthopedic
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address SMITH & NEPHEW RICHARDS, INC. 1450 Brooks Rd. memphis, TN 38116

Supplemental Filings

Supplement NumberDateSupplement Type
P810020Original Filing
S005 1998-09-14 Real-time Process
S004 1995-07-20 Normal 180 Day Track
S003 1991-11-05 Normal 180 Day Track
S002 1988-12-12 Normal 180 Day Track
S001 1984-06-04

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.